drugset / Trial / NCT02684578
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
Phase 2
Completed
66 enrolled
University of California, San Francisco
California Retina Consultants · collabNorthwestern University · collabOregon Health and Science University · collabRetina Health Center · collabRetinal Consultants Medical Group · collabSan Francisco Veterans Affairs Medical Center · collabUniversity of California, Davis · collabUniversity of California, San Diego · collabUniversity of Illinois at Chicago · collabVA Palo Alto Health Care System · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
Timeline
- Start
- 2016-04
- Primary completion
- 2022-04
- Completion
- 2022-10
Outcome
Missed primary endpoint
registry analysis (superiority test); Metformin vs Observation; p = 0.39 NCT02684578 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | — | Oral |